TY - JOUR
T1 - Managing hematological cancer patients during the COVID-19 pandemic :
T2 - an ESMO-EHA Interdisciplinary Expert Consensus
AU - Buske, Christian
AU - Dreyling, M.
AU - Álvarez Larrán, Alberto
AU - Apperley, Jane
AU - Arcaini, Luca
AU - Besson, Caroline
AU - Bullinger, Lars
AU - Corradini, Paolo
AU - Della Porta, Matteo Giovanni
AU - Dimopoulos, Meletios
AU - D'Sa, Shirley
AU - Eich, H.T.
AU - Foà, R.
AU - Ghia, P.
AU - da Silva, M.G.
AU - Gribben, J.
AU - Hajek, Roman
AU - Harrison, C.
AU - Heuser, M.
AU - Kiesewetter, Barbara
AU - Kiladjian, Jean-Jacques
AU - Kroeger, Nicolaus
AU - Moreau, Philippe
AU - Passweg, Jakob R.
AU - Peyvandi, Flora
AU - Rea, Delphine
AU - Ribera, Jose-Maria
AU - Robak, Tadeusz
AU - San-Miguel, J
AU - Santini, Valeria
AU - Sanz, G.
AU - Sonneveld, P.
AU - Von Lilienfeld-Toal, M.
AU - Wendtner, Clemens-Martin
AU - Pentheroudakis, G.
AU - Passamonti, Francesco
PY - 2022
Y1 - 2022
N2 - Background: The COVID-19 pandemic has created enormous challenges for the clinical management of patients with hematological malignancies (HMs), raising questions about the optimal care of this patient group. Methods: This consensus manuscript aims at discussing clinical evidence and providing expert advice on statements related to the management of HMs in the COVID-19 pandemic. For this purpose, an international consortium was established including a steering committee, which prepared six working packages addressing significant clinical questions from the COVID-19 diagnosis, treatment, and mitigation strategies to specific HMs management in the pandemic. During a virtual consensus meeting, including global experts and lead by the European Society for Medical Oncology and the European Hematology Association, statements were discussed and voted upon. When a consensus could not be reached, the panel revised statements to develop consensual clinical guidance. Results and conclusion: The expert panel agreed on 33 statements, reflecting a consensus, which will guide clinical decision making for patients with hematological neoplasms during the COVID-19 pandemic.
AB - Background: The COVID-19 pandemic has created enormous challenges for the clinical management of patients with hematological malignancies (HMs), raising questions about the optimal care of this patient group. Methods: This consensus manuscript aims at discussing clinical evidence and providing expert advice on statements related to the management of HMs in the COVID-19 pandemic. For this purpose, an international consortium was established including a steering committee, which prepared six working packages addressing significant clinical questions from the COVID-19 diagnosis, treatment, and mitigation strategies to specific HMs management in the pandemic. During a virtual consensus meeting, including global experts and lead by the European Society for Medical Oncology and the European Hematology Association, statements were discussed and voted upon. When a consensus could not be reached, the panel revised statements to develop consensual clinical guidance. Results and conclusion: The expert panel agreed on 33 statements, reflecting a consensus, which will guide clinical decision making for patients with hematological neoplasms during the COVID-19 pandemic.
KW - COVID-19
KW - Hematological malignancies
KW - Consensus manuscript
U2 - 10.1016/j.esmoop.2022.100403
DO - 10.1016/j.esmoop.2022.100403
M3 - Article
C2 - 35272130
SN - 2059-7029
VL - 7
JO - ESMO Open
JF - ESMO Open
IS - 2
ER -
